Strategic partnerships to develop novel therapeutics.
At PTC, we are committed to discovering, developing and commercializing therapeutics that address disorders with high unmet medical needs. Strategic collaborations provide expanded opportunities to apply PTC's scientific approach to additional therapeutic areas. We seek alliances and partnerships with leading biopharmaceutical and advocacy groups.
We currently have ongoing collaborations with Roche and the SMA Foundation for the development and commercialization of compounds for the treatment of spinal muscular atrophy. We have received grant funding from the Wellcome Trust for the research and development of small molecule compounds that selectively decrease the production of BMI1 expression in tumor stem cells. In addition, the Wellcome Trust granted us funding for the research and development of small molecule compounds that target life-threatening infections caused by multi-drug resistant Gram-negative bacteria.